Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
5.9K
Vaccinations01:51

Vaccinations

53.7K
Overview
53.7K
Vaccines01:21

Vaccines

41
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
41

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent trajectories of antiviral memory after SARS-CoV-2 infection.

Nature communications·2022
Same author

Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.

Infection and immunity·2022
Same author

Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal- experience, challenges and lessons learnt.

Human vaccines & immunotherapeutics·2022
Same author

Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity.

The Journal of infection·2022
Same author

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV.

JCI insight·2022
Same author

CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination.

JCI insight·2022

Related Experiment Video

Updated: Mar 29, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.6K

RSV vaccine use--the missing data.

Simon B Drysdale1,2, Charles J Sande1, Christopher A Green1

  • 1a Oxford Vaccine Group, Department of Paediatrics , University of Oxford , Oxford , UK.

Expert Review of Vaccines
|December 5, 2015
PubMed
Summary

Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations and mortality globally. More data on RSV epidemiology, transmission, and costs are needed to guide effective vaccination strategies and public health policy.

Keywords:
RSVcost–effectiveness modeepidemiologyhealth economicsrespiratory syncytial virusvaccineviral transmission

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.5K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.4K

Related Experiment Videos

Last Updated: Mar 29, 2026

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.6K
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

17.5K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.4K

Area of Science:

  • * Virology and Epidemiology
  • * Public Health and Vaccinology

Background:

  • * Respiratory syncytial virus (RSV) is a primary driver of infant hospitalizations and a leading cause of global infant mortality.
  • * Prevention via vaccination is a critical public health objective, yet implementation faces data gaps.

Purpose of the Study:

  • * To highlight the need for comprehensive epidemiological data on RSV.
  • * To underscore the importance of understanding RSV transmission dynamics and associated healthcare costs.
  • * To inform the development of effective vaccination strategies and health economic models for RSV control.

Main Methods:

  • * Review of existing literature on RSV epidemiology and disease burden.
  • * Identification of critical data gaps in understanding RSV transmission and economic impact.
  • * Emphasis on the necessity of data for health economic modeling.

Main Results:

  • * Significant lack of detailed epidemiological data across diverse settings and age groups for RSV.
  • * Limited understanding of RSV transmission patterns and the economic burden of the disease.
  • * Urgent requirement for data to support vaccine program implementation and policy decisions.

Conclusions:

  • * Robust epidemiological data is essential for successful RSV vaccination programs.
  • * Further research is needed to quantify RSV transmission and healthcare costs.
  • * Data-driven insights are crucial for optimizing public health interventions against RSV.